open access

Vol 2, No 1 (2011)
Review paper
Published online: 2011-03-24
Get Citation

Treatment of patients with Philadelphia positive acute lymphoblastic leukemia

Sebastian Giebel, Beata Piątkowska-Jakubas, Maria Adamczyk-Cioch, Anna Czyż, Janusz Hałka, Małgorzata Krawczyk-Kuliś, Ewa Lech-Marańda, Jarosław Piszcz, Beata Stella-Hołowiecka, Anna Polakiewicz, Jerzy Hołowiecki
Hematologia 2011;2(1):33-42.

open access

Vol 2, No 1 (2011)
REVIEW ARTICLES
Published online: 2011-03-24

Abstract

Translocation (9;22)(q34:q11.2), called Philadelphia chromosome (Ph), is the most frequent cytogenetic aberration among adults with acute lymphoblastic leukemia (ALL). Before the era of tyrosine kinase inhibitors (TKI), ALL Ph+ was associated with particularly poor prognosis. Introduction of imatinib (IM) in combination with induction-consolidation chemotherapy increased complete remission rate to over 90% and allowed application of allogeneic hematopoietic stem cell transplantation to greater proportion of patients. First reports on long term results indicate that 5-year probability of the overall survival is now approximately 50%. Further improvement requires prospective clinical trials aimed to optimize the protocols of IM administration and evaluate potential role of 2nd generation TKI in the up-front therapy of adults with ALL Ph+.
Hematologia 2011; 2, 1: 33–41

Abstract

Translocation (9;22)(q34:q11.2), called Philadelphia chromosome (Ph), is the most frequent cytogenetic aberration among adults with acute lymphoblastic leukemia (ALL). Before the era of tyrosine kinase inhibitors (TKI), ALL Ph+ was associated with particularly poor prognosis. Introduction of imatinib (IM) in combination with induction-consolidation chemotherapy increased complete remission rate to over 90% and allowed application of allogeneic hematopoietic stem cell transplantation to greater proportion of patients. First reports on long term results indicate that 5-year probability of the overall survival is now approximately 50%. Further improvement requires prospective clinical trials aimed to optimize the protocols of IM administration and evaluate potential role of 2nd generation TKI in the up-front therapy of adults with ALL Ph+.
Hematologia 2011; 2, 1: 33–41
Get Citation

Keywords

acute lymphoblastic leukemia; Philadelphia chromosome; imatinib; tyrosine kinase inhibitors; therapy; transplantation

About this article
Title

Treatment of patients with Philadelphia positive acute lymphoblastic leukemia

Journal

Hematology in Clinical Practice

Issue

Vol 2, No 1 (2011)

Article type

Review paper

Pages

33-42

Published online

2011-03-24

Bibliographic record

Hematologia 2011;2(1):33-42.

Keywords

acute lymphoblastic leukemia
Philadelphia chromosome
imatinib
tyrosine kinase inhibitors
therapy
transplantation

Authors

Sebastian Giebel
Beata Piątkowska-Jakubas
Maria Adamczyk-Cioch
Anna Czyż
Janusz Hałka
Małgorzata Krawczyk-Kuliś
Ewa Lech-Marańda
Jarosław Piszcz
Beata Stella-Hołowiecka
Anna Polakiewicz
Jerzy Hołowiecki

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.